Product nameAnti-Prothrombin antibody
See all Prothrombin primary antibodies
DescriptionRabbit polyclonal to Prothrombin
Tested applicationsSuitable for: ICC/IF, RIA, IP, WB, ELISAmore details
Species reactivityReacts with: Human
Full length native protein: Human prothrombin purified from human plasma
Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.
Storage bufferPreservative: 0.01% Thimerosal (merthiolate)
Constituents: 50% Glycerol, PBS, pH 7.5
Concentration information loading...
PurityProtein G purified
Our Abpromise guarantee covers the use of ab48627 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|ICC/IF||Use a concentration of 1 - 5 µg/ml.|
|RIA||Use at an assay dependent concentration.|
|IP||Use at an assay dependent concentration.|
|WB||Use at an assay dependent concentration. Predicted molecular weight: 70 kDa.|
|ELISA||Use at an assay dependent concentration.|
FunctionThrombin, which cleaves bonds after Arg and Lys, converts fibrinogen to fibrin and activates factors V, VII, VIII, XIII, and, in complex with thrombomodulin, protein C. Functions in blood homeostasis, inflammation and wound healing.
Tissue specificityExpressed by the liver and secreted in plasma.
Involvement in diseaseDefects in F2 are the cause of factor II deficiency (FA2D) [MIM:613679]. It is a very rare blood coagulation disorder characterized by mucocutaneous bleeding symptoms. The severity of the bleeding manifestations correlates with blood factor II levels.
Genetic variations in F2 may be a cause of susceptibility to ischemic stroke (ISCHSTR) [MIM:601367]; also known as cerebrovascular accident or cerebral infarction. A stroke is an acute neurologic event leading to death of neural tissue of the brain and resulting in loss of motor, sensory and/or cognitive function. Ischemic strokes, resulting from vascular occlusion, is considered to be a highly complex disease consisting of a group of heterogeneous disorders with multiple genetic and environmental risk factors.
Defects in F2 are a cause of susceptibility to thrombosis (THR) [MIM:188050]. It is a multifactorial disorder of hemostasis characterized by abnormal platelet aggregation in response to various agents and recurrent thrombi formation. Note=A common genetic variation in the 3-prime untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increased risk of venous thrombosis.
Sequence similaritiesBelongs to the peptidase S1 family.
Contains 1 Gla (gamma-carboxy-glutamate) domain.
Contains 2 kringle domains.
Contains 1 peptidase S1 domain.
modificationsThe gamma-carboxyglutamyl residues, which bind calcium ions, result from the carboxylation of glutamyl residues by a microsomal enzyme, the vitamin K-dependent carboxylase. The modified residues are necessary for the calcium-dependent interaction with a negatively charged phospholipid surface, which is essential for the conversion of prothrombin to thrombin.
Cellular localizationSecreted > extracellular space.
- Information by UniProt
FormCleaved into the following 4 chains: 1. Activation peptide fragment 1 2. Activation peptide fragment 2 3. Thrombin light chain 4. Thrombin heavy chain
- coagulation factor II (thrombin) antibody
- Coagulation factor II antibody
- F2 antibody
ICC/IF image of ab48627 stained HepG2 cells. The cells were 4% PFA fixed (10 min) and then incubated in 1%BSA / 10% normal goat serum / 0.3M glycine in 0.1% PBS-Tween for 1h to permeabilise the cells and block non-specific protein-protein interactions. The cells were then incubated with the antibody (ab48627, 1µg/ml) overnight at +4°C. The secondary antibody (green)ÿwas Alexa Fluor© 488 goat anti-rabbit IgG (H+L) used at a 1/1000 dilution for 1h. Alexa Fluor© 594 WGA was used to label plasma membranes (red) at a 1/200 dilution for 1h. DAPI was used to stain the cell nuclei (blue) at a concentration of 1.43µM.
This product has been referenced in:
- Verrills NM et al. Identification of Novel Diagnostic Biomarkers for Asthma and Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med : (2011). WB ; Human . Read more (PubMed: 21471098) »
- Hernández-Espinosa D et al. Inhibition of proteasome by bortezomib causes intracellular aggregation of hepatic serpins and increases the latent circulating form of antithrombin. Lab Invest 88:306-17 (2008). Read more (PubMed: 18195690) »